ARCHIVES

Cell Behavior Changes Noted At Baltimore Symposium

This article is from The Cancer Letter archive.

Vol. 08 No. 02 | January 8, 1982

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Only 10% Of Breast Cancer Patients May Benefit From Contralateral Mastectomy

March 26, 2010

Cancer Policy: EMFs “Possible” Carcinogen, Panel Says; Plans Public Hearings

August 7, 1998

Immunotherapy Demonstrates Disease Control in Phase II Study

September 28, 2012

Cancer death rate dropping 1.1 percent a year, annual report finds.

October 7, 2005

R.S.K. Young Quits As FDA Oncology Group Leader

July 11, 1980